GitNux Logo
  • Editorial Process
Contact Us
Gitnux Logo
Contact Us
  • Home
  • Editorial Process
  • Contact Us
Gitnux Logo
  • Home
  • Blog
  • All Statistics
  • Services
  • Company
  • Privacy Policy
  • Contact
  • Partner
  • Careers
  • As Seen In

Our Services

Custom Market Research

Tailored research solutions designed around your specific business questions and strategic objectives.

Learn more →

Buy Industry Reports

Access comprehensive pre-made industry reports with instant download. Professional market intelligence at your fingertips.

Browse reports →

Software Advisory

Stop wasting months evaluating software vendors. Our analysts leverage 1,000+ AI-verified Best Lists to recommend the right tool for your business in 2–4 weeks.

Learn more →

Popular Categories

Ai In IndustryTechnology Digital MediaSafety AccidentsEntertainment EventsMedical Conditions DisordersMental Health PsychologyMarketing AdvertisingEducation LearningFinance Financial ServicesManufacturing EngineeringSocial Issues Societal TrendsPublic Safety CrimeHealthcare MedicineFood NutritionConsumer RetailHealth MedicineConstruction InfrastructureSports RecreationHr In IndustryDiversity Equity And Inclusion In IndustryGlobal Regional IndustriesBusiness FinanceCustomer Experience In IndustrySustainability In Industry

Find us on

Clutch · Sortlist · DesignRush · G2

GoodFirms · Crunchbase · Tracxn

How we make money

Gitnux.org is an independent market research platform. Primarily, we generate revenue on Gitnux through research projects we conduct for clients & external banner advertising. If we receive a commission for products or services, this is indicated with *.

© 2026 Gitnux. Independent market research platform.

Logos provided by Logo.dev

  1. Home
  2. Medical Conditions Disorders
  3. Bowel Cancer Statistics

GITNUXREPORT 2026

Bowel Cancer Statistics

A common deadly cancer's burden is rising despite effective screening and prevention.

140 statistics5 sections11 min readUpdated 19 days ago

Key Statistics

Statistic 1

In 2020, colorectal cancer was the third most common cancer worldwide with approximately 1.93 million new cases, representing 10.0% of all cancer cases

Statistic 2

Globally, colorectal cancer ranks as the second leading cause of cancer death with 935,000 deaths in 2020, accounting for 9.3% of all cancer deaths

Statistic 3

In the United States, an estimated 153,020 new cases of colorectal cancer are expected to be diagnosed in 2024

Statistic 4

Colorectal cancer incidence rates in the US have been declining by about 1% per year from 2011 to 2021, largely due to screening

Statistic 5

In the UK, there were 42,892 new cases of bowel cancer diagnosed in 2017-2019, averaging 117 cases per day

Statistic 6

Bowel cancer incidence in the UK is higher in males with an age-standardised rate of 56.4 per 100,000 compared to 39.1 per 100,000 in females

Statistic 7

Lifetime risk of developing colorectal cancer in the US is about 1 in 24 for men and 1 in 26 for women

Statistic 8

In Europe, colorectal cancer incidence varies widely from 29.3 per 100,000 in Eastern Europe to 49.7 per 100,000 in Western Europe for men

Statistic 9

Australia has one of the highest colorectal cancer incidence rates globally at 40.5 per 100,000 for males

Statistic 10

In 2022, China reported over 500,000 new colorectal cancer cases, making it the third most common cancer there

Statistic 11

Colorectal cancer rates are rising in adults under 50 in the US, with a 1-2% annual increase since 1995

Statistic 12

In the US, rectal cancer incidence among adults aged 20-49 increased by 29% from 1999 to 2018

Statistic 13

Globally, colorectal cancer burden is projected to increase by 55% to 3 million new cases by 2040

Statistic 14

In Japan, colorectal cancer is the most common cancer with 147,000 new cases annually as of 2020

Statistic 15

Age-standardised incidence rate for colorectal cancer in the US is 19.7 per 100,000 in 2021

Statistic 16

In Canada, 26,800 new colorectal cancer cases were diagnosed in 2023

Statistic 17

Incidence of colorectal cancer in India is lower at 4.4 per 100,000 but rising due to westernization

Statistic 18

In South Korea, colorectal cancer incidence peaked at 44.7 per 100,000 in 2011 but stabilized recently

Statistic 19

European Union saw 447,400 new colorectal cancer cases in 2022

Statistic 20

In Brazil, colorectal cancer incidence is 17.5 per 100,000, ranking fourth among cancers

Statistic 21

US men have a 4.3% lifetime probability of colorectal cancer diagnosis

Statistic 22

Women in the US have a 4.0% lifetime risk of colorectal cancer

Statistic 23

In the UK, bowel cancer is the fourth most common cancer, with 1 in 15 men and 1 in 19 women developing it in their lifetime

Statistic 24

Global age-standardised incidence rate for colorectal cancer is 19.7 per 100,000 in both sexes

Statistic 25

In 2020, 60% of colorectal cancer cases occurred in high or very high HDI countries

Statistic 26

US colorectal cancer incidence declined 35% from 1985 to 2020 in older adults

Statistic 27

In Europe, Northern countries have higher colorectal cancer incidence at 40-50 per 100,000 vs 20-30 in South

Statistic 28

Iran reports 12,500 new colorectal cancer cases yearly

Statistic 29

In Saudi Arabia, colorectal cancer incidence is 8.3 per 100,000, rising rapidly

Statistic 30

New Zealand has high rates at 38.9 per 100,000 for males

Statistic 31

Colorectal cancer screening reduces mortality by 30-50% in screened populations

Statistic 32

Colonoscopy every 10 years from age 45 reduces colorectal cancer incidence by 68% and mortality by 53%

Statistic 33

FIT annual screening detects 75% of colorectal cancers, reduces mortality by 33%

Statistic 34

Sigmoidoscopy once or twice lifetime reduces CRC incidence by 21-26% and mortality by 22-31%

Statistic 35

Polyp removal during colonoscopy prevents 75-90% of cancers from those polyps

Statistic 36

USPSTF recommends screening ages 45-75 grade A, 76-85 grade C selectively

Statistic 37

Aspirin 81mg daily for 10+ years reduces CRC incidence by 20% in average risk

Statistic 38

High-fiber diet (>30g/day) associated with 20% lower CRC risk

Statistic 39

Limiting red/processed meat to <18oz/week reduces risk by 17%

Statistic 40

Regular physical activity (150min/week moderate) lowers CRC risk by 25%

Statistic 41

Maintaining healthy weight prevents 11% of colorectal cancers

Statistic 42

No alcohol best, but <1 drink/day minimal risk increase vs >2/day 20% higher

Statistic 43

Screening uptake in US 67% in 2021, up from 52% in 2008

Statistic 44

CT colonography every 5 years detects 90% cancers, 80% large polyps

Statistic 45

Blood-based multi-cancer detection tests like Shield detect CRC signal in 83% stage I

Statistic 46

Vitamin D supplementation 1000IU/day may reduce advanced adenoma recurrence by 27%

Statistic 47

Calcium 1200mg/day reduces polyp recurrence by 15-20%

Statistic 48

UK Bowel Cancer Screening Programme (FIT age 60-74) detects 90% cancers, 10% uptake for colonoscopy

Statistic 49

Post-polypectomy surveillance: high-risk polyps recur in 25-40% at 3 years without

Statistic 50

Familial risk screening starts age 40 or 10 years before youngest case

Statistic 51

Quitting smoking reduces CRC risk to non-smoker levels after 20 years

Statistic 52

Mediterranean diet adherence lowers CRC risk by 20-30%

Statistic 53

Screening in 50-75 year olds prevents 1000 CRC deaths per 100,000 screened lifetime

Statistic 54

gFOBT annual reduces mortality by 16%

Statistic 55

Cologuard (mt-sDNA) every 3 years: 92% cancer sensitivity

Statistic 56

Early screening age 45 now recommended due to rising young-onset CRC

Statistic 57

Probiotics may reduce adenoma formation by 15% in trials

Statistic 58

Age is the biggest risk factor with 90% of colorectal cancers diagnosed in people over 50 worldwide

Statistic 59

Family history increases colorectal cancer risk 2-3 fold if a first-degree relative is affected before age 50

Statistic 60

Inflammatory bowel disease like ulcerative colitis raises lifetime colorectal cancer risk to 30% after 35 years

Statistic 61

Type 2 diabetes is associated with a 30% increased risk of colorectal cancer

Statistic 62

Smoking increases colorectal cancer risk by 20-30%, especially rectal cancer by 50% in long-term smokers

Statistic 63

Obesity (BMI >30) raises colorectal cancer risk by 1.3 times, with stronger effect in men

Statistic 64

Red meat consumption over 500g/week increases risk by 17%, processed meat by 18% per 50g daily

Statistic 65

Alcohol intake of >30g/day increases colorectal cancer risk by 25%

Statistic 66

Sedentary lifestyle doubles the risk of colon cancer compared to highly active individuals

Statistic 67

Lynch syndrome carries 50-80% lifetime risk of colorectal cancer

Statistic 68

FAP (Familial Adenomatous Polyposis) results in nearly 100% colorectal cancer risk by age 40 without intervention

Statistic 69

Aspirin use reduces colorectal cancer risk by 20-30% with long-term daily use

Statistic 70

Hormone replacement therapy in postmenopausal women lowers colorectal cancer risk by 20-40%

Statistic 71

High calcium intake (>1000mg/day) is linked to 15-20% reduced colorectal cancer risk

Statistic 72

Low folate levels increase risk by 20%

Statistic 73

Previous polyps: adenomatous polyps increase future cancer risk 10-20 fold depending on number and size

Statistic 74

African Americans have 20% higher colorectal cancer incidence and 40% higher mortality than whites

Statistic 75

First-degree family history doubles risk, second-degree increases by 1.5 times

Statistic 76

Helicobacter pylori infection may increase colorectal cancer risk by 2-3 times

Statistic 77

Gallstones or cholecystectomy associated with 20% higher proximal colon cancer risk

Statistic 78

Shift work disrupting circadian rhythms increases risk by 30-40%

Statistic 79

High glycemic load diet raises risk by 25%

Statistic 80

Statin use for 5+ years reduces colorectal cancer risk by 30%

Statistic 81

Pelvic radiation for other cancers increases risk 2-4 fold

Statistic 82

Chronic NSAID use lowers risk by 40-50% but with GI bleeding risks

Statistic 83

Tall stature (>1.8m) linked to 15% higher risk per 5cm increase

Statistic 84

Low vitamin D levels (<12 ng/mL) associated with 30% increased risk

Statistic 85

Change in bowel habits occurs in 75% of colorectal cancer patients

Statistic 86

Blood in stool is reported in 40-60% of colorectal cancer cases at diagnosis

Statistic 87

Abdominal pain or cramping present in 50-70% of patients with colon cancer

Statistic 88

Unexplained weight loss in 40% of advanced colorectal cancer patients

Statistic 89

Iron deficiency anemia, especially in men and postmenopausal women, signals right-sided colon cancer in 60% cases

Statistic 90

Tenesmus (feeling of incomplete evacuation) common in rectal cancer affecting 30-50%

Statistic 91

Narrow stools or pencil-thin caliber in 20-30% due to rectal obstruction

Statistic 92

Colonoscopy detects 95% of colorectal cancers and 70-90% of large polyps

Statistic 93

Fecal immunochemical test (FIT) has 79% sensitivity for cancer, 23-40% for advanced adenomas

Statistic 94

CT colonography sensitivity for colorectal cancer is 90-96%

Statistic 95

CEA tumor marker elevated in 70% of advanced colorectal cancers but only 40% early stage

Statistic 96

60% of colorectal cancers are diagnosed at stage III or IV

Statistic 97

Digital rectal exam detects 10-20% of rectal cancers

Statistic 98

Flexible sigmoidoscopy visualizes 60% of colorectal cancers (distal)

Statistic 99

MRI staging for rectal cancer has 85-90% accuracy for T stage, 70-80% for N stage

Statistic 100

Endoscopic ultrasound for rectal cancer T staging accuracy 80-90%, N staging 70-75%

Statistic 101

Multi-target stool DNA test detects 92% of cancers, 42% advanced neoplasia

Statistic 102

PET-CT useful for detecting metastases with 90% sensitivity in colorectal cancer

Statistic 103

Fatigue due to anemia in 20-30% of colon cancer patients at presentation

Statistic 104

Nausea/vomiting in 10-20% from obstruction

Statistic 105

Jaundice if liver mets, in 5-10% advanced cases

Statistic 106

Biopsy confirmation required in 100% of colorectal cancer diagnoses

Statistic 107

Right-sided cancers more likely asymptomatic early (50%), left-sided symptomatic (70%)

Statistic 108

Guaiac-based FOBT sensitivity 13-50% for cancer

Statistic 109

85% of colorectal cancers arise from adenomatous polyps over 10+ years

Statistic 110

TNM staging: Stage I 15% of diagnoses

Statistic 111

Stage II 20-25%, Stage III 25-30%, Stage IV 20-25% at diagnosis in US

Statistic 112

5-year survival for localized colorectal cancer is 91%

Statistic 113

Regional spread colorectal cancer 5-year survival 73%

Statistic 114

Distant metastatic colorectal cancer 5-year survival 15%

Statistic 115

Overall 5-year relative survival for colorectal cancer in US is 65% (2014-2020)

Statistic 116

Surgery alone for stage I colon cancer achieves 90-95% 5-year survival

Statistic 117

Adjuvant FOLFOX chemotherapy for stage III colon cancer improves 5-year survival from 50% to 70%

Statistic 118

Bevacizumab added to first-line chemo for metastatic CRC increases median survival from 20 to 21.7 months

Statistic 119

Cetuximab in KRAS wild-type mCRC improves median survival to 23.5 months vs 20.0

Statistic 120

Total mesorectal excision (TME) for rectal cancer improves local recurrence from 30-40% to 5-10%

Statistic 121

Neoadjuvant chemoradiation for locally advanced rectal cancer downstages 50-60% of tumors

Statistic 122

Liver resection for resectable colorectal liver mets achieves 5-year survival 40-60%

Statistic 123

Immunotherapy (pembrolizumab) for MSI-H/dMMR mCRC has 40% objective response rate

Statistic 124

Regorafenib in refractory mCRC extends median survival by 1.4 months to 6.4 months

Statistic 125

10-year survival for stage II colon cancer is 80-85% post-surgery

Statistic 126

CAPOX regimen non-inferior to FOLFOX in stage III, with 75% 3-year DFS

Statistic 127

HIPEC for peritoneal carcinomatosis in CRC improves median survival to 30 months vs 12

Statistic 128

Encorafenib + cetuximab for BRAF V600E mCRC doubles median survival to 15 months

Statistic 129

Watch-and-wait after complete clinical response to neoadjuvant therapy in rectal cancer: 3-year non-regrowth 78%

Statistic 130

TAS-102 (trifluridine-tipiracil) in refractory mCRC median OS 7.1 vs 5.3 months

Statistic 131

Fruquintinib in mCRC extends OS to 7.4 months vs 4.8

Statistic 132

Stage IV colon cancer 5-year survival improved from 10% in 2000 to 15% in 2020 due to better systemic therapy

Statistic 133

Short-course radiotherapy for rectal cancer reduces local recurrence to 6% vs 15% long-course

Statistic 134

Nivolumab for MSI-H mCRC ORR 31%, median PFS 14 months

Statistic 135

Adjuvant atezolizumab fails to improve DFS in stage III MSI-H CRC

Statistic 136

Robotic surgery for rectal cancer lowers conversion rate to 2% vs 10% laparoscopic, similar survival

Statistic 137

90% of stage I rectal cancers cured by local excision alone

Statistic 138

Median survival for untreated metastatic CRC is 6-12 months

Statistic 139

FOLFIRI + panitumumab in RAS WT mCRC median PFS 10.1 months

Statistic 140

Overall survival for right-sided vs left-sided mCRC: 19 vs 27 months with anti-EGFR

1/140
Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortuneMicrosoftWorld Economic ForumFast Company
Harvard Business ReviewThe GuardianFortune+497
Rachel Svensson

Written by Rachel Svensson·Edited by Olivia Thornton·Fact-checked by Maya Johansson

Published Feb 13, 2026·Last verified Apr 1, 2026·Next review: Oct 2026
Fact-checked via 4-step process— how we build this report
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

While colorectal cancer strikes a devastating blow globally as the second leading cause of cancer death, claiming nearly a million lives in 2020, a beacon of hope shines through its proven preventability with timely screening and informed lifestyle choices.

Key Takeaways

  • 1In 2020, colorectal cancer was the third most common cancer worldwide with approximately 1.93 million new cases, representing 10.0% of all cancer cases
  • 2Globally, colorectal cancer ranks as the second leading cause of cancer death with 935,000 deaths in 2020, accounting for 9.3% of all cancer deaths
  • 3In the United States, an estimated 153,020 new cases of colorectal cancer are expected to be diagnosed in 2024
  • 4Age is the biggest risk factor with 90% of colorectal cancers diagnosed in people over 50 worldwide
  • 5Family history increases colorectal cancer risk 2-3 fold if a first-degree relative is affected before age 50
  • 6Inflammatory bowel disease like ulcerative colitis raises lifetime colorectal cancer risk to 30% after 35 years
  • 7Change in bowel habits occurs in 75% of colorectal cancer patients
  • 8Blood in stool is reported in 40-60% of colorectal cancer cases at diagnosis
  • 9Abdominal pain or cramping present in 50-70% of patients with colon cancer
  • 105-year survival for localized colorectal cancer is 91%
  • 11Regional spread colorectal cancer 5-year survival 73%
  • 12Distant metastatic colorectal cancer 5-year survival 15%
  • 13Colorectal cancer screening reduces mortality by 30-50% in screened populations
  • 14Colonoscopy every 10 years from age 45 reduces colorectal cancer incidence by 68% and mortality by 53%
  • 15FIT annual screening detects 75% of colorectal cancers, reduces mortality by 33%

A common deadly cancer's burden is rising despite effective screening and prevention.

Incidence & Prevalence

1In 2020, colorectal cancer was the third most common cancer worldwide with approximately 1.93 million new cases, representing 10.0% of all cancer cases
Verified
2Globally, colorectal cancer ranks as the second leading cause of cancer death with 935,000 deaths in 2020, accounting for 9.3% of all cancer deaths
Verified
3In the United States, an estimated 153,020 new cases of colorectal cancer are expected to be diagnosed in 2024
Verified
4Colorectal cancer incidence rates in the US have been declining by about 1% per year from 2011 to 2021, largely due to screening
Directional
5In the UK, there were 42,892 new cases of bowel cancer diagnosed in 2017-2019, averaging 117 cases per day
Single source
6Bowel cancer incidence in the UK is higher in males with an age-standardised rate of 56.4 per 100,000 compared to 39.1 per 100,000 in females
Verified
7Lifetime risk of developing colorectal cancer in the US is about 1 in 24 for men and 1 in 26 for women
Verified
8In Europe, colorectal cancer incidence varies widely from 29.3 per 100,000 in Eastern Europe to 49.7 per 100,000 in Western Europe for men
Verified
9Australia has one of the highest colorectal cancer incidence rates globally at 40.5 per 100,000 for males
Directional
10In 2022, China reported over 500,000 new colorectal cancer cases, making it the third most common cancer there
Single source
11Colorectal cancer rates are rising in adults under 50 in the US, with a 1-2% annual increase since 1995
Verified
12In the US, rectal cancer incidence among adults aged 20-49 increased by 29% from 1999 to 2018
Verified
13Globally, colorectal cancer burden is projected to increase by 55% to 3 million new cases by 2040
Verified
14In Japan, colorectal cancer is the most common cancer with 147,000 new cases annually as of 2020
Directional
15Age-standardised incidence rate for colorectal cancer in the US is 19.7 per 100,000 in 2021
Single source
16In Canada, 26,800 new colorectal cancer cases were diagnosed in 2023
Verified
17Incidence of colorectal cancer in India is lower at 4.4 per 100,000 but rising due to westernization
Verified
18In South Korea, colorectal cancer incidence peaked at 44.7 per 100,000 in 2011 but stabilized recently
Verified
19European Union saw 447,400 new colorectal cancer cases in 2022
Directional
20In Brazil, colorectal cancer incidence is 17.5 per 100,000, ranking fourth among cancers
Single source
21US men have a 4.3% lifetime probability of colorectal cancer diagnosis
Verified
22Women in the US have a 4.0% lifetime risk of colorectal cancer
Verified
23In the UK, bowel cancer is the fourth most common cancer, with 1 in 15 men and 1 in 19 women developing it in their lifetime
Verified
24Global age-standardised incidence rate for colorectal cancer is 19.7 per 100,000 in both sexes
Directional
25In 2020, 60% of colorectal cancer cases occurred in high or very high HDI countries
Single source
26US colorectal cancer incidence declined 35% from 1985 to 2020 in older adults
Verified
27In Europe, Northern countries have higher colorectal cancer incidence at 40-50 per 100,000 vs 20-30 in South
Verified
28Iran reports 12,500 new colorectal cancer cases yearly
Verified
29In Saudi Arabia, colorectal cancer incidence is 8.3 per 100,000, rising rapidly
Directional
30New Zealand has high rates at 38.9 per 100,000 for males
Single source

Incidence & Prevalence Interpretation

While screening successes give us a hopeful nod in older populations, the grim reality is a global juggernaut claiming nearly a million lives annually, with an alarming and stubborn rise among the young ensuring its future reign.

Prevention & Screening

1Colorectal cancer screening reduces mortality by 30-50% in screened populations
Verified
2Colonoscopy every 10 years from age 45 reduces colorectal cancer incidence by 68% and mortality by 53%
Verified
3FIT annual screening detects 75% of colorectal cancers, reduces mortality by 33%
Verified
4Sigmoidoscopy once or twice lifetime reduces CRC incidence by 21-26% and mortality by 22-31%
Directional
5Polyp removal during colonoscopy prevents 75-90% of cancers from those polyps
Single source
6USPSTF recommends screening ages 45-75 grade A, 76-85 grade C selectively
Verified
7Aspirin 81mg daily for 10+ years reduces CRC incidence by 20% in average risk
Verified
8High-fiber diet (>30g/day) associated with 20% lower CRC risk
Verified
9Limiting red/processed meat to <18oz/week reduces risk by 17%
Directional
10Regular physical activity (150min/week moderate) lowers CRC risk by 25%
Single source
11Maintaining healthy weight prevents 11% of colorectal cancers
Verified
12No alcohol best, but <1 drink/day minimal risk increase vs >2/day 20% higher
Verified
13Screening uptake in US 67% in 2021, up from 52% in 2008
Verified
14CT colonography every 5 years detects 90% cancers, 80% large polyps
Directional
15Blood-based multi-cancer detection tests like Shield detect CRC signal in 83% stage I
Single source
16Vitamin D supplementation 1000IU/day may reduce advanced adenoma recurrence by 27%
Verified
17Calcium 1200mg/day reduces polyp recurrence by 15-20%
Verified
18UK Bowel Cancer Screening Programme (FIT age 60-74) detects 90% cancers, 10% uptake for colonoscopy
Verified
19Post-polypectomy surveillance: high-risk polyps recur in 25-40% at 3 years without
Directional
20Familial risk screening starts age 40 or 10 years before youngest case
Single source
21Quitting smoking reduces CRC risk to non-smoker levels after 20 years
Verified
22Mediterranean diet adherence lowers CRC risk by 20-30%
Verified
23Screening in 50-75 year olds prevents 1000 CRC deaths per 100,000 screened lifetime
Verified
24gFOBT annual reduces mortality by 16%
Directional
25Cologuard (mt-sDNA) every 3 years: 92% cancer sensitivity
Single source
26Early screening age 45 now recommended due to rising young-onset CRC
Verified
27Probiotics may reduce adenoma formation by 15% in trials
Verified

Prevention & Screening Interpretation

The data presents a clear, life-saving equation: by diligently combining recommended screenings, prudent lifestyle choices, and even some simple supplements, we hold a powerful and multi-layered defense against colorectal cancer, making it one of the most preventable malignancies.

Risk Factors

1Age is the biggest risk factor with 90% of colorectal cancers diagnosed in people over 50 worldwide
Verified
2Family history increases colorectal cancer risk 2-3 fold if a first-degree relative is affected before age 50
Verified
3Inflammatory bowel disease like ulcerative colitis raises lifetime colorectal cancer risk to 30% after 35 years
Verified
4Type 2 diabetes is associated with a 30% increased risk of colorectal cancer
Directional
5Smoking increases colorectal cancer risk by 20-30%, especially rectal cancer by 50% in long-term smokers
Single source
6Obesity (BMI >30) raises colorectal cancer risk by 1.3 times, with stronger effect in men
Verified
7Red meat consumption over 500g/week increases risk by 17%, processed meat by 18% per 50g daily
Verified
8Alcohol intake of >30g/day increases colorectal cancer risk by 25%
Verified
9Sedentary lifestyle doubles the risk of colon cancer compared to highly active individuals
Directional
10Lynch syndrome carries 50-80% lifetime risk of colorectal cancer
Single source
11FAP (Familial Adenomatous Polyposis) results in nearly 100% colorectal cancer risk by age 40 without intervention
Verified
12Aspirin use reduces colorectal cancer risk by 20-30% with long-term daily use
Verified
13Hormone replacement therapy in postmenopausal women lowers colorectal cancer risk by 20-40%
Verified
14High calcium intake (>1000mg/day) is linked to 15-20% reduced colorectal cancer risk
Directional
15Low folate levels increase risk by 20%
Single source
16Previous polyps: adenomatous polyps increase future cancer risk 10-20 fold depending on number and size
Verified
17African Americans have 20% higher colorectal cancer incidence and 40% higher mortality than whites
Verified
18First-degree family history doubles risk, second-degree increases by 1.5 times
Verified
19Helicobacter pylori infection may increase colorectal cancer risk by 2-3 times
Directional
20Gallstones or cholecystectomy associated with 20% higher proximal colon cancer risk
Single source
21Shift work disrupting circadian rhythms increases risk by 30-40%
Verified
22High glycemic load diet raises risk by 25%
Verified
23Statin use for 5+ years reduces colorectal cancer risk by 30%
Verified
24Pelvic radiation for other cancers increases risk 2-4 fold
Directional
25Chronic NSAID use lowers risk by 40-50% but with GI bleeding risks
Single source
26Tall stature (>1.8m) linked to 15% higher risk per 5cm increase
Verified
27Low vitamin D levels (<12 ng/mL) associated with 30% increased risk
Verified

Risk Factors Interpretation

These statistics confirm that while our fifties may bring wisdom, they also deliver an uninvited guest list of risk factors, from your family tree and your fridge to your couch and your circadian rhythm, but also remind us that proactive measures exist to turn the odds in our favor.

Symptoms & Diagnosis

1Change in bowel habits occurs in 75% of colorectal cancer patients
Verified
2Blood in stool is reported in 40-60% of colorectal cancer cases at diagnosis
Verified
3Abdominal pain or cramping present in 50-70% of patients with colon cancer
Verified
4Unexplained weight loss in 40% of advanced colorectal cancer patients
Directional
5Iron deficiency anemia, especially in men and postmenopausal women, signals right-sided colon cancer in 60% cases
Single source
6Tenesmus (feeling of incomplete evacuation) common in rectal cancer affecting 30-50%
Verified
7Narrow stools or pencil-thin caliber in 20-30% due to rectal obstruction
Verified
8Colonoscopy detects 95% of colorectal cancers and 70-90% of large polyps
Verified
9Fecal immunochemical test (FIT) has 79% sensitivity for cancer, 23-40% for advanced adenomas
Directional
10CT colonography sensitivity for colorectal cancer is 90-96%
Single source
11CEA tumor marker elevated in 70% of advanced colorectal cancers but only 40% early stage
Verified
1260% of colorectal cancers are diagnosed at stage III or IV
Verified
13Digital rectal exam detects 10-20% of rectal cancers
Verified
14Flexible sigmoidoscopy visualizes 60% of colorectal cancers (distal)
Directional
15MRI staging for rectal cancer has 85-90% accuracy for T stage, 70-80% for N stage
Single source
16Endoscopic ultrasound for rectal cancer T staging accuracy 80-90%, N staging 70-75%
Verified
17Multi-target stool DNA test detects 92% of cancers, 42% advanced neoplasia
Verified
18PET-CT useful for detecting metastases with 90% sensitivity in colorectal cancer
Verified
19Fatigue due to anemia in 20-30% of colon cancer patients at presentation
Directional
20Nausea/vomiting in 10-20% from obstruction
Single source
21Jaundice if liver mets, in 5-10% advanced cases
Verified
22Biopsy confirmation required in 100% of colorectal cancer diagnoses
Verified
23Right-sided cancers more likely asymptomatic early (50%), left-sided symptomatic (70%)
Verified
24Guaiac-based FOBT sensitivity 13-50% for cancer
Directional
2585% of colorectal cancers arise from adenomatous polyps over 10+ years
Single source
26TNM staging: Stage I 15% of diagnoses
Verified
27Stage II 20-25%, Stage III 25-30%, Stage IV 20-25% at diagnosis in US
Verified

Symptoms & Diagnosis Interpretation

While your colon may send up a distress flare with a 75% chance of changed habits, the sobering truth is that by the time you notice, there's a 60% chance the enemy is already entrenched at stage III or IV, despite a colonoscope's 95% detection rate quietly waiting in the wings for its overdue spotlight.

Treatment & Survival

15-year survival for localized colorectal cancer is 91%
Verified
2Regional spread colorectal cancer 5-year survival 73%
Verified
3Distant metastatic colorectal cancer 5-year survival 15%
Verified
4Overall 5-year relative survival for colorectal cancer in US is 65% (2014-2020)
Directional
5Surgery alone for stage I colon cancer achieves 90-95% 5-year survival
Single source
6Adjuvant FOLFOX chemotherapy for stage III colon cancer improves 5-year survival from 50% to 70%
Verified
7Bevacizumab added to first-line chemo for metastatic CRC increases median survival from 20 to 21.7 months
Verified
8Cetuximab in KRAS wild-type mCRC improves median survival to 23.5 months vs 20.0
Verified
9Total mesorectal excision (TME) for rectal cancer improves local recurrence from 30-40% to 5-10%
Directional
10Neoadjuvant chemoradiation for locally advanced rectal cancer downstages 50-60% of tumors
Single source
11Liver resection for resectable colorectal liver mets achieves 5-year survival 40-60%
Verified
12Immunotherapy (pembrolizumab) for MSI-H/dMMR mCRC has 40% objective response rate
Verified
13Regorafenib in refractory mCRC extends median survival by 1.4 months to 6.4 months
Verified
1410-year survival for stage II colon cancer is 80-85% post-surgery
Directional
15CAPOX regimen non-inferior to FOLFOX in stage III, with 75% 3-year DFS
Single source
16HIPEC for peritoneal carcinomatosis in CRC improves median survival to 30 months vs 12
Verified
17Encorafenib + cetuximab for BRAF V600E mCRC doubles median survival to 15 months
Verified
18Watch-and-wait after complete clinical response to neoadjuvant therapy in rectal cancer: 3-year non-regrowth 78%
Verified
19TAS-102 (trifluridine-tipiracil) in refractory mCRC median OS 7.1 vs 5.3 months
Directional
20Fruquintinib in mCRC extends OS to 7.4 months vs 4.8
Single source
21Stage IV colon cancer 5-year survival improved from 10% in 2000 to 15% in 2020 due to better systemic therapy
Verified
22Short-course radiotherapy for rectal cancer reduces local recurrence to 6% vs 15% long-course
Verified
23Nivolumab for MSI-H mCRC ORR 31%, median PFS 14 months
Verified
24Adjuvant atezolizumab fails to improve DFS in stage III MSI-H CRC
Directional
25Robotic surgery for rectal cancer lowers conversion rate to 2% vs 10% laparoscopic, similar survival
Single source
2690% of stage I rectal cancers cured by local excision alone
Verified
27Median survival for untreated metastatic CRC is 6-12 months
Verified
28FOLFIRI + panitumumab in RAS WT mCRC median PFS 10.1 months
Verified
29Overall survival for right-sided vs left-sided mCRC: 19 vs 27 months with anti-EGFR
Directional

Treatment & Survival Interpretation

In the battle against colorectal cancer, survival is a strict and unforgiving geography, where your odds are best if the enemy is caught at home base, still decent if it's raiding the neighboring counties, but become a desperate and heroic struggle if it has already established beachheads in distant lands.

Sources & References

  • WHO logo
    Reference 1
    WHO
    who.int
    Visit source
  • CANCER logo
    Reference 2
    CANCER
    cancer.org
    Visit source
  • CANCERRESEARCHUK logo
    Reference 3
    CANCERRESEARCHUK
    cancerresearchuk.org
    Visit source
  • CANCER logo
    Reference 4
    CANCER
    cancer.gov
    Visit source
  • ECIS logo
    Reference 5
    ECIS
    ecis.jrc.ec.europa.eu
    Visit source
  • GCO logo
    Reference 6
    GCO
    gco.iarc.who.int
    Visit source
  • PUBMED logo
    Reference 7
    PUBMED
    pubmed.ncbi.nlm.nih.gov
    Visit source
  • CDC logo
    Reference 8
    CDC
    cdc.gov
    Visit source
  • GANJOHO logo
    Reference 9
    GANJOHO
    ganjoho.jp
    Visit source
  • SEER logo
    Reference 10
    SEER
    seer.cancer.gov
    Visit source
  • CANCER logo
    Reference 11
    CANCER
    cancer.ca
    Visit source
  • GCO logo
    Reference 12
    GCO
    gco.iarc.fr
    Visit source
  • CROHNSCOLITISFOUNDATION logo
    Reference 13
    CROHNSCOLITISFOUNDATION
    crohnscolitisfoundation.org
    Visit source
  • WCRF logo
    Reference 14
    WCRF
    wcrf.org
    Visit source
  • GENOME logo
    Reference 15
    GENOME
    genome.gov
    Visit source
  • UPTODATE logo
    Reference 16
    UPTODATE
    uptodate.com
    Visit source
  • IARC logo
    Reference 17
    IARC
    iarc.who.int
    Visit source
  • NHS logo
    Reference 18
    NHS
    nhs.uk
    Visit source
  • MAYOCLINIC logo
    Reference 19
    MAYOCLINIC
    mayoclinic.org
    Visit source
  • WEBMD logo
    Reference 20
    WEBMD
    webmd.com
    Visit source
  • RADIOLOGYINFO logo
    Reference 21
    RADIOLOGYINFO
    radiologyinfo.org
    Visit source
  • ASGE logo
    Reference 22
    ASGE
    asge.org
    Visit source
  • NCBI logo
    Reference 23
    NCBI
    ncbi.nlm.nih.gov
    Visit source
  • MACMILLAN logo
    Reference 24
    MACMILLAN
    macmillan.org.uk
    Visit source
  • NCCN logo
    Reference 25
    NCCN
    nccn.org
    Visit source
  • USPREVENTIVESERVICESTASKFORCE logo
    Reference 26
    USPREVENTIVESERVICESTASKFORCE
    uspreventiveservicestaskforce.org
    Visit source
  • NEJM logo
    Reference 27
    NEJM
    nejm.org
    Visit source
  • AICR logo
    Reference 28
    AICR
    aicr.org
    Visit source
  • ACR logo
    Reference 29
    ACR
    acr.org
    Visit source
  • GI logo
    Reference 30
    GI
    gi.org
    Visit source
  • ACPONLINE logo
    Reference 31
    ACPONLINE
    acponline.org
    Visit source

Logos provided by Logo.dev

On this page

  1. 01Key Takeaways
  2. 02Incidence & Prevalence
  3. 03Prevention & Screening
  4. 04Risk Factors
  5. 05Symptoms & Diagnosis
  6. 06Treatment & Survival
Rachel Svensson

Rachel Svensson

Author

Olivia Thornton
Editor
Maya Johansson
Fact Checker

Our Commitment to Accuracy

  • Rigorous fact-checking process
  • Data from reputable sources
  • Regular updates to ensure relevance
Learn more

Explore More In This Category

  • Lung Cancer Treatment Statistics
  • Pregnancy Complications Statistics
  • Neurofibromatosis Statistics
  • Afib Statistics
  • Autism Spectrum Disorder Statistics
  • Adhd Misdiagnosis Statistics